Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New schizophrenia drug LB-102 moves to large safety trial

NCT ID NCT07369154

Disease control Sponsor: LB Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 4 times

Summary

This study is testing the long-term safety of a new medication called LB-102 for adults with stable schizophrenia. About 900 participants will take the drug for 52 weeks to see what side effects occur. The goal is to make sure the drug is safe enough for ongoing use to control schizophrenia symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 900 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provide ICF * Patients clinically stable PANSS \</= 80 at screening * CGI-S \</+ 3 at screening * Medically stable * BMI 18 -40 * Taking oral antipsychotic treatment for at least 30 days * Have stable living environment Exclusion Criteria: * Sexually active M/F patients not willing to use highly effective contraception * Breast feeding * History of treatment resistance to schizophrenia medications * DSM-5 current diagnosis other than schizophrenia * Risk of suicidal behavior * History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizophrenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Schizophrenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    23 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Accelerated Clinical Trial

    RECRUITING

    Snellville, Georgia, 30078, United States

  • Adams Clinical

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Adams Clinical

    RECRUITING

    DeSoto, Texas, 75115, United States

  • Advanced Research Center

    RECRUITING

    Anaheim, California, 92805, United States

  • Arch Clinical Trials

    RECRUITING

    St Louis, Missouri, 63141, United States

  • CenExel

    RECRUITING

    Culver City, California, 92845, United States

  • CenExel

    RECRUITING

    Hollywood, Florida, 33024, United States

  • CenExel

    RECRUITING

    Atlanta, Georgia, 30331, United States

  • CenExel Gaithersburg

    RECRUITING

    Gaithersburg, Maryland, 20877, United States

  • Chandler Clinical Trials

    RECRUITING

    Chandler, Arizona, 85224, United States

  • Health Synergy Clinical Research

    RECRUITING

    West Palm Beach, Florida, 33407, United States

  • Neuro-Behavioral Clinical Research

    RECRUITING

    New York, New York, 11516, United States

  • Neuro-Behavioral Clinical Research

    RECRUITING

    Canton, Ohio, 44720, United States

  • Pillar Clinical Research

    RECRUITING

    Bentonville, Arkansas, 72712, United States

  • Pillar Clinical Research

    RECRUITING

    Little Rock, Arkansas, 72204, United States

  • Pillar Clinical Research

    RECRUITING

    Chicago, Illinois, 60641, United States

  • Pillar Clinical Research

    RECRUITING

    Richardson, Texas, 75080, United States

    Contact Email: •••••@•••••

  • ProScience Research Group

    RECRUITING

    Culver City, California, 90230, United States

  • Redbird Research

    RECRUITING

    Las Vegas, Nevada, 89119, United States

  • Segal Trials

    RECRUITING

    Miami Lakes, Florida, 33063, United States

  • Synapse Clinical Trials

    RECRUITING

    Cerritos, California, 90703, United States

  • Synergy San Diego

    RECRUITING

    San Diego, California, 92064, United States

  • Woodland International Research Group

    RECRUITING

    Little Rock, Arkansas, 72211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.